Equities Analysts Set Expectations for Haemonetics Co.’s Q3 2025 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for shares of Haemonetics in a research report issued on Wednesday, August 28th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $1.22 per share for the quarter, up from their prior forecast of $1.20. The consensus estimate for Haemonetics’ current full-year earnings is $4.58 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.21 EPS, FY2025 earnings at $4.55 EPS, Q1 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.22 EPS, Q4 2026 earnings at $1.40 EPS and FY2026 earnings at $5.10 EPS.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The firm had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.05 earnings per share.

A number of other analysts have also recently weighed in on HAE. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Citigroup decreased their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. Barrington Research upped their price target on shares of Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a research report on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $107.50.

Haemonetics Stock Up 0.3 %

Shares of Haemonetics stock opened at $75.58 on Monday. The company has a fifty day moving average price of $83.28 and a 200 day moving average price of $83.87. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. Haemonetics has a twelve month low of $70.74 and a twelve month high of $97.97. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of 33.00, a price-to-earnings-growth ratio of 1.38 and a beta of 0.29.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the transaction, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the transaction, the executive vice president now owns 21,410 shares of the company’s stock, valued at $1,926,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the transaction, the insider now directly owns 18,196 shares in the company, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. 1.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP acquired a new stake in Haemonetics during the second quarter worth about $39,000. TFO Wealth Partners LLC boosted its holdings in shares of Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 589 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 438 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Haemonetics in the second quarter valued at approximately $82,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Haemonetics in the second quarter valued at approximately $83,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.